Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Assessing cardiovascular and kidney health using metabolomics in patients with heart disease

Official title: Cardiovascular-Renal Adverse oUtcome rIsk aSsessment systEm for Coronary Heart Disease Complicated With Chronic Kidney Disease Based on Targeted Lipid METabolomics

Run by China-Japan Friendship Hospital · NCT06383208 · Data updated 2026-11-12

This study is testing if certain fat-related substances in the blood can help predict health outcomes for adults with both heart disease and kidney problems.

More Chronic Kidney Diseases trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment470 (estimated)
SponsorChina-Japan Friendship Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedApril 1, 2024
Main results expectedMarch 31, 2027
Study endsMarch 31, 2027
Registry record updatedApril 25, 2024
Trial IDNCT06383208 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18-80 diagnosed with coronary heart disease and chronic kidney disease.

Probably not a fit

Patients with severe psychiatric illnesses, end-stage renal disease, or those who have undergone kidney transplantation may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the relationship between lipid metabolites and the prognosis of patients suffering from both coronary heart disease (CHD) and chronic kidney disease (CKD). By analyzing specific lipid metabolites that are elevated in patients with reduced kidney function, the study seeks to identify potential biomarkers that could indicate adverse outcomes. The research focuses on patients aged 18-80 who have been diagnosed with CHD and have clarified renal function status. The findings could provide insights into the cardiovascular-kidney-metabolic syndrome and improve risk assessment for these patients.

Why it matters

Potential benefit: If successful, this study could lead to improved prognostic assessments and targeted interventions for patients with both coronary heart disease and chronic kidney disease.

How similar studies have gone: While the approach of using lipid metabolomics is emerging, similar studies have shown promise in identifying biomarkers for cardiovascular and renal diseases.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age 18-80 years old;
2. Diagnosed with CHD during hospitalization through coronary angiography, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation acute coronary syndrome (NST-ACS), stable angina pectoris;
3. Patients with clarified renal function status.;

CKD is defined as meeting one of the following criteria, with a duration of more than 3 months: eGFR \< 60 ml/min/1.73 m² or eGFR ≥ 60 ml/min/1.73 m² and urinary albumin-to-creatinine ratio (uACR) ≥ 30 mg/g;

Exclusion Criteria:

1. Pregnancy or lactation;
2. Severe valve disease or severe mechanical complications requiring surgical intervention;
3. Severe psychiatric illness or other reasons that impede follow-up compliance;
4. Severe hematologic disorders or end-stage malignant tumors;
5. Having undergone kidney transplantation or long-term maintenance dialysis;
6. Severe liver disease (Child-Pugh class C);
7. Received acute renal failure dialysis treatment within 12 weeks prior to screening for enrollment;
8. Severe chronic lung disease requiring long-term mechanical ventilation support or awaiting lung transplantation;
9. Life expectancy less than 1 year.

Where it's running

  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.